Takeda

Photo
11.09.2024 • NewsStrategy

Pharma’s Digital Transformation

Industry experts Michelangelo Canzoneri, Josef Trapl, Wolfgang Winter, Christian Woelbeling, and Thomas Zimmer – all members of ISPE’s Pharma 4.0 guide core team – explain the transformational challenges and critical success factors of the digital Pharma 4.0 journey.

Photo
30.03.2023 • News

Takeda Plans New Plant for Plasma-derived Therapies

Japanese drugmaker Takeda plans to invest about $765 million to build a new manufacturing facility in Osaka for plasma-derived therapies (PDTs). The company said the sum is the largest-ever investment to expand capacity in Japan and the plant will also be the biggest of its kind in the country.

Photo
16.12.2022 • News

Takeda Takes Nimbus Lakshmi for $4 Billion

Japanese pharma Takeda is acquiring Nimbus Lakshmi, a wholly-owned subsidiary of US clinical-stage drug discovery company Nimbus Therapeutics, and its tyrosine kinase 2 (TYK2) inhibitor NDI-034858, which is undergoing trials for treating multiple autoimmune diseases, including psoriasis.

Photo
02.11.2021 • News

Takeda Takes GammaDelta Therapeutics

Following a multi-year collaboration, Japanese pharma Takeda has exercised its option to buy the UK’s GammaDelta Therapeutics for a pre-negotiated upfront sum, as well as future potential development and regulatory milestone payments. Takeda expects the acquisition to be finalized during the first quarter of its 2022 fiscal year.

Photo
13.09.2021 • News

Japan Orders 150 Million Takeda-made Novavax Doses

Japanese drugmaker Takeda has clarified its plans to produce and distribute the Novavax Covid-19 shot in the country, if and when it is approved. After several delays, in its last announcement the US biotech said it planned to apply to the US Food and Drug Administration (FDA) for Emergency Use Authorization in this year’s fourth quarter.

Photo
07.09.2021 • NewsStrategy

A Roadmap for Pharma 4.0

Industry experts Josef Trapl, Wolfgang Winter, Christian Woelbeling, and Thomas Zimmer – all members of ISPE’s Pharma 4.0 group – talk about the idea behind ISPE’s Pharma 4.0 initiative and the challenges on the way to realize the digital transformation of the pharmaceutical industry.

Photo
02.09.2021 • News

Rovi Says Particles in Moderna Vials Were Metal Splinters

The question of what kind of particulate matter found its way into vials of Moderna’s Covid-19 vaccine deployed in Japan may have been resolved. There is as yet indication that contaminated doses may have caused the deaths of two men who had received the US biotech’s shot days earlier.

Photo
06.11.2020 • News

Moderna Taps Takeda to Distribute Vaccine in Japan

US vaccine manufacturer Moderna has tapped Takeda as marketing partner for its Covid-19 vaccine candidate mRNA-1273f in Japan. Financial terms of the deal were not disclosed. The Japanese drugmaker will import and distribute the vaccine starting in the first half of next year as well as handle local regulatory approvals. The original contract is for 50 million doses.

Photo
27.08.2020 • News

Takeda Sells OTC Arm to Blackstone

As rumored earlier this month, private equity group Blackstone has emerged as the winning bidder for Takeda’s consumer healthcare business. The transaction is expected to close by Mar. 31, 2021, subject to the usual closing conditions and regulatory approvals.

Photo
20.08.2020 • News

Blackstone Mooted as Buyer for Takeda’s OTC Arm

Japanese pharma Takeda is apparently winding down the asset-shedding drive it launched following the $59 billion acquisition of Shire. The company is currently said to be in talks to sell its domestic consumer health (OTC) business to US private equity investor Blackstone.

41 more articles

Whitepaper

Excellence in Pharmaceutical Distribution and The Critical Role of Good Distribution Practice (GDP)
Setting the Standard

Excellence in Pharmaceutical Distribution and The Critical Role of Good Distribution Practice (GDP)

Are you ready to elevate your pharmaceutical operations? Download our exclusive whitepaper and discover how compliance with Good Distribution Practice (GDP) is essential for the safety and integrity of pharmaceuticals.